Recruiting PHASE1 INTERVENTIONAL 3-arm NCT03289949

The Neurobiological Effect of 5-HT2AR Modulation (NeuroPharm2)

Sponsor: Gitte Moos Knudsen

Updated 10 times since 2017 Last updated: Dec 13, 2024 Started: Mar 3, 2017 Primary completion: Jun 1, 2030 Completion: Jun 1, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03289949, this PHASE1 trial focuses on Basic Science and remains actively recruiting participants. Sponsored by Gitte Moos Knudsen, it has been updated 10 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

10 versions recorded

Jan 2025 — Present [monthly]

Recruiting PHASE1
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Nov 2023 — Jul 2024 [monthly]

Recruiting PHASE1
Sep 2022 — Nov 2023 [monthly]

Recruiting PHASE1

▶ Show 5 earlier versions

Jan 2021 — Sep 2022 [monthly]

Recruiting PHASE1
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE1

Status: Unknown Status → Recruiting
Feb 2020 — Sep 2020 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jun 2018 — Feb 2020 [monthly]

Recruiting PHASE1
Oct 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Mar 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gitte Moos Knudsen

Data source: Rigshospitalet, Denmark

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Copenhagen, Denmark